On August 29, The Life Sciences Discovery Fund (LSDF) announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations to promote translation of health-related technologies from the laboratory to the commercial marketplace. Nexgenia’s project to develop and validate technology for increasing the speed and efficiency of cell separations for cancer immunotherapy and other applications was awarded one of these grants. The LSDF Board of Trustees selected the awardees following review of proposals for scientific and technical merit, commercial potential, and health and economic benefits to Washington. Click here to read the full press release.
“We are excited to make additional investments in the areas of autoimmune disorders and cancer and to expand our grant-making reach into lung disease management,” said John DesRosier, LSDF executive director.
Nexgenia is excited to accelerate its efforts in cell separations by leveraging our expertise in magnetic nanoparticle and stimuli-responsive polymer technology.